

Form 7 – Monthly CSE Progress Report May 2022
Form 7 – Monthly CSE Progress Report June 2022 Name of Listed Issuer: Trading Symbol:
BioMark Diagnostics Inc., providing universal access to cancer diagnostics and early stage detection by leveraging the power of new technology.
BioMark Diagnostics is leading the world in early-stage cancer detection with an oncology focus designed to improve patient outcomes.
Form 7 – Monthly CSE Progress Report June 2022 Name of Listed Issuer: Trading Symbol:
A liquid biopsy is a test that is performed on a sample of blood taken
The article presented on this page may contain forward-looking statements. These statements relate to future
The Right Leadership and Technology Partnerships designed to deliver clinical solutions to cancer care management.
Earlier and faster cancer detection is underway in Alberta Mikenomics | April 6, 2021 Earlier
A new project funded by the Canadian Cancer Society (CCS) could transform how lung cancer
Dr. Myron “Mike” Weisfeldt is the 2021 recipient of the American Heart Association’s distinguished Watkins-Saunders
Biotech companies are showing leadership in early detection of cancer. March 16, 2021 Melanie Schaffer ,
Mar 16, 2021 | staff reporter NEW YORK — BioMark Diagnostics said on Tuesday that its collaborators
No paperwork, no hassle. We keep things digital, easy and regular.
*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.
1 604 370 0779
130 3851 Shell Road
Richmond BC
Canada V6X 2W2
Rashid A. Bux (CEO)
[email protected]